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The extrathoracic subclavian venous approach is a new approach with the aim to exclude
the disadvantages of the conventional subclavian venous approach that carries a risk of
pneumothorax and may result in lead damage. We investigated long-term survival of the leads
implanted by this new approach between May 1995 and June 2005. A total of 482 leads
implanted in 309 patients were analyzed. In cases of patient death, meeting criteria for lead
failure or diﬃculty of continuing follow-up for other reasons, the follow-up was terminated at
that time. Therefore, the follow-up was complete for 358 leads (74.3%) and the mean follow-
up time was 55:0 32:1 months (range 1–122 months). The overall lead survival rate was
100% at 5 years and 98.3% at 7 years. This ﬁnding suggested that this approach might reduce
the incidence of lead failure.
(J Arrhythmia 2006; 22: 110–114)
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Introduction
The conventional subclavian venous approach
(CSA) is still the most commonly performed method
for implantation of pacemaker (PM) leads.1,2) It has
been widely accepted for its speed, simplicity and
ease for multiple leads insertion. Despite its popular-
ity, the CSA has a well-known complication during
the procedure and has the potential of damaging the
lead.3–7) To avoid these peculiar troubles with the
CSA, the extrathoracic subclavian venous approach
(ESA) has gradually become popular in recent
years.8–14) The aim of this study was to assess the
long-term survival of leads implanted with the ESA.
Method
A total of 482 leads implanted in 309 patients
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using ESA were included in this analysis. Indications
for pacing are showed in Table 1. When the lead
placement failed using the ESA, the axillary venous
approach (AA) was applied as an alternative to the
ESA. All lead implants occurred between May 1995
and June 2005 and had at least 1 month of follow-up.
Implant Technique
The subclavian vein extends from the take-oﬀ of
the internal jugular vein to the inferior margin of the
ﬁrst rib. It goes under the subclavius muscle and the
costoclavicular ligament when it emerges from the
thoracic cavity, and then becomes extrathoracic as it
crosses the ﬁrst rib. The subclavian vein becomes the
axillary vein that continues to the brachial vein at the
outer margin of the pectoralis major muscle. The
placement of the lead via the extrathoracic subcla-
vian vein and the axillary vein avoids possible
entrapment in the soft tissues associated with the
clavicle. Moreover since the extrathoracic subclavi-
an vein is punctured on the ﬁrst rib that blocks the
needle to advance into the lung, the ESA minimizes
the risk of pneumothorax and lung injury.6–17)
Infrequently puncturing of the extrathoracic subcla-
vian vein was diﬃcult because it was hidden just
beneath the clavicle or constricted by the needle
puncture. In such cases, the AA was applied as a
second choice15–17) (Figure 1).
With the ESA, after preparation and draping of the
sterile ﬁeld, 1% lidocaine is used for local anes-
thesia. An incision long enough to accommodate the
pulse generator to be used is made approximately
2 cm below and parallel to the left or right clavicle.
The incision is made from the junction of the medial
and middle thirds of the clavicle to the outside.
Dissection is carried out to the prepectoralis fascia,
and a pocket is then developed in the prepectoralis
fascia, using blunt dissection. The needle is inserted
into the extrathoracic subclavian vein following
venography with 10–15ml of a 1:1 contrast medium:
normal saline solution. After entry, a guide wire is
placed and the dilator sheath set follows. The dilator
and sheath are advanced over the guide wire into
the subclavian vein and superior vena cava. After
removal of the guide wire and dilator, the lead is
advanced through the sheath. The lead is then placed
within the chamber in the usual fashion.
Follow-up
Telemetric ECG monitoring was started immedi-
ately after the procedure, and biplane chest X rays
were obtained the following day to rule out evidence
of pneumothorax and lead dislodgement. Each
patient was followed at 1 week, 1 month, 3 months,
6 months, 1 year and yearly after PM implantation
to monitor lead dislodgement and infection and to
Table 1 Indications for pacing in 309 patients.
Patients
Indication No. %
SSS 149 48.2
AVB 102 33.0
AF bradycardia 58 18.8
Total 309 100.0
Conventional
Subclavian
Venous Approach
Axillary Venous Approach
Extrathoracic Subclavian
Venous Approach
Coracoclavicular
ligament
Second rib
Cephalic vein
Cut–down
Sterno–mastoid
muscle Scalenus anterior
muscle
Internal
Jugular Vein
Costoclavicular
ligament
Subclavius
muscle
Subclavian
vein
Axillary
vein
Sternum First rib
Figure 1 Illustration of anatomical fea-
tures and venous accesses for four diﬀerent
insertion techniques.
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reprogram to the appropriate pacing/sensing param-
eters.
Data Collection
The patient’s characteristics were retrospectively
obtained from the medical records and follow up
data from the PM clinic in our hospital. The mean
age of the patients at the time of the implant was
75:6 9:6 years (range 41–98). From a total of 309
patients, 149 (48.2%) were males and 160 (51.8%)
were females and 27 (8.7%) were under 65 years.
One hundred ninety-four leads (40.2%) were im-
planted in the atrium and 288 leads (59.8%) were
implanted in the ventricle. The distribution of venous
access was 92.3% extrathoracic subclavian (n ¼ 445
leads) and 7.7% axillary (n ¼ 37 leads). The implan-
tations were performed mainly using the left-side
approach (n ¼ 294 patients (95.1%)).
Lead Models
In our patients, 46 pacing lead models, from 8
manufacturers were used. The lead mix relative to
chamber and polarity was 34 (7.1%) ventricular
unipolar, 221 (45.9%) ventricular bipolar, 18 (3.7%)
atrial unipolar, 176 (36.5%) atrial bipolar, 3 (0.6%)
single pass VDD unipolar and 30 (6.2%) single pass
VDD bipolar leads. The distribution of lead polarity
was unipolar in 55 leads (11.4%), and bipolar in 427
leads (88.6%). The ﬁxation mechanism was active in
6 leads (1.2%), and passive in 476 leads (98.8%).
The lead insulation materials were 477 (99.0%)
silicone and 5 (1.0%) polyurethane (Table 2).
Lead Performance
Lead failure was deﬁned as follows: (1) visible
conductor fracture or insulation break seen radio-
graphically or observed in the operating room, (2)
the lead impedance measured by telemetry indicat-
ing 5200 ohm, =2000 ohm in conventional lead or
=3000 ohm in high-impedance lead and a drop of
more than 50% from the initially measured value at
follow-up visit 3–4 months after lead implantation,
or (3) use of the lead being discontinued because of
loss of capture, loss of sensing failure, oversensing,
muscular stimulation and elevated thresholds.
Statistical Analysis
Cumulative survival rate, as an object of the atrial
and ventricular leads implanted by the extrathoracic
subclavian venous approach and/or the axillary
venous approach, was calculated with Kaplan–
Meyer method.
Result
The follow-up ended at the time of patient death,
fulﬁlled criteria for lead failure, or impossibility of
follow-up for reasons unrelated to lead failure (e.g.,
infection, transfer to other hospitals). All the follow-
ups ended on June 31, 2005. Therefore, the follow-
up was complete in 358 leads (74.3%). The mean
follow-up duration was 55:0 32:1 months (range
1–122 months). The overall lead survival for the lead
population is shown in Table 3. Two cases of
ventricular lead failure were discovered in this
study. One case was a 56-year-old male who had a
DDD-PM with an atrial bipolar lead and a ventric-
ular unipolar lead. The impedance of his ventricular
lead abruptly indicated >9999 ohm with no ventric-
ular output 6 years after implantation. But the
insulation break as well as the lead fracture could
not be found in spite of careful examination on
Table 2 All implanted leads by polarity, insulation and ﬁxation.
Polarity Insulation Fixation
Position Unipolar Bipolar Silicone Urethane Active Passive
Atrial 18 176 193 1 0 194
Ventricular 34 221 251 4 6 249
Single pass VDD 3 30 33 0 0 33
Total 55 427 477 5 6 476
Table 3 Long-term survival of 482 endocardial pacing
leads.
Years from
implant
Survival
(No.)
Failure
(No.)
Cumulative
Survival (%)
3 151 0 100
4 123 0 100
5 84 0 100
6 63 1 98.8
7 44 0 98.3
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biplane chest X rays, under ﬂuoroscopy and in the
operating room. Another case was an 89-year-old
female whose ventricular bipolar lead showed a
complete fracture just on the connector block in the
generator pocket 6.5 years after implantation. Her
back was severely bowed from working in her ﬁeld,
and it could be deduced that her repetitive arm
motions had forced the generator head to bend the
fractured part of the ventricular lead. In the former
it was not quite clear why the lead was damaged and
in the latter it was considered that the lead fracture
was unrelated to the method for lead implantation.
Therefore by excluding the latter case from this
study, the overall lead survival rate was 100.0% at
5 years and 98.3% at 7 years. Since the number of
patients with follow-up > 7 years is too small to
allow reliable statistical analysis of probability of
lead failure, their results are excluded (Table 3). No
major complications related to this procedure such as
pneumothorax, hemothorax, brachial plexus injury
and vascular damage were observed.
Discussion
Lead survival may be linked to the implanted lead
model, insulation material, polarity, route of venous
access, age and gender registered.18–22) Further,
diﬀerences of deﬁnitions and criteria make the
comparison diﬃcult in the literatures on lead
survival. It is known that the unipolar leads survive
signiﬁcantly longer than the bipolar leads and that
polyurethane leads might induce inner insulation
failure due to metal ion oxidation.21,23–25) The leads
used in this study were mostly bipolar (88.6%) with
silicone rubber insulation (99.0%) and included no
speciﬁc lead models that were reported to have a
poor performance. Helguera et al. found no dif-
ferences in lead failure for patient sex, lead polarity,
ﬁxation mechanism, implantation route, insulation
material or types of polyurethane, and reported the
overall survival rates of endocardial pacing leads
implanted 5 and 10 years were 96.4% and 93.6%,
respectively, using CSA and had 51 lead failures
(2.2%) out of 2298 leads when applying their soft
analysis for suspected structural lead failure similar
to ours.20) Our lead survival was 100.0% at 5 years
and 98.3% at 7 years with one lead failure (0.2%) out
of 482 leads.
The cephalic vein cut-down approach (CCA) has
longer lead survival than the CSA.3,5,7,18,22,25,26) The
high rate of lead survival is based on the fact that the
leads inserted by the CCA pass into the thorax
through the subclavian vein cavity and thus are able
to avoid being entrapped in the subclavian soft
tissues. The literature suggests that lead fractures
mostly occur as they pass just beneath the clavi-
cle.3–18,22,25,27) Lead fracture might not only cause
life-threatening events in PM dependent patients but
also require invasive corrective procedures that are
troublesome and possibly hazards in PM independ-
ent patients. Previously we examined on chest X-ray
ﬁlms with the upper extremity exercise of PM
implant side in 116 patients and suggested that the
CSA has a high incidence of two types of stress (i.e.
subclavian traction of 84.6% and compression of
11.5%), while the ESA apparently has a lower stress
rate with the traction of 3.1% and none of compres-
sion.27)
There were no major complications including
pneumothorax in the present study. Aggarwal et al.
and Lloyd et al. reported the incidence of pneumo-
thorax with CSA was low rate of 1.9% and 1.0%
respectively,28,29) while Gardini et al. experienced no
pneumothorax with the ESA.12)
Limitation
A limitation of the present study is the small
sample size and that the implanted leads were mostly
silicone rubber and bipolar leads. Abandonment by
reprogramming for reasons other than lead failure
(e.g., atrial ﬁbrillation) was not covered.
Conclusion
The ESA recently has been accepted to a degree
and much has been reported about its safety and
eﬀectiveness as a technique for lead insertion;
however its acceptance seems to be insuﬃcient. To
the best of our knowledge, literature related to the
long-term follow-up of the leads implanted with this
approach has not yet been published. The present
study showed that the ESA has a high lead survival
rate in a 7-year period. Our data also suggested that
the placement of endocardial leads using the ESA
should be accepted as the standard method and the
CSA should be discontinued as soon as possible
because of poor lead survival and procedure-related
risk. To establish whether the ESA boosts the lead
survival, further investigations with a long-term
follow-up are needed.
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